Roche’s High-End China Strategy
ChinaBio Today submits:
Roche Holding AG (RHHBY.PK) will continue to implement its high-end pharma strategy in emerging markets, continuing to focus on the expensive, innovative drugs for which it is well known, rather than seeking to compete in the generic market.
"Our strategy, in contrast to many of our peers, is to sell differentiated products with clear clinical benefits, [because they] are cost-effective and can sustain higher prices," said Pascal Soriot, Chief Operating Officer of Roche’s Pharmaceutical Division, in a Dow Jones Newswires interview (see story).